Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes-Reference-Cited by-同舟云学术

Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes

Published:2022-05-29 Issue:8 Volume:24 Page:1598-1606
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Zaccardi Francesco¹²³^ORCID,Kloecker David E.¹²^ORCID,Khunti Kamlesh¹²³^ORCID,Davies Melanie J.²⁴^ORCID

Affiliation:

1. Leicester Real World Evidence Unit University of Leicester, Leicester General Hospital Leicester UK

2. Diabetes Research Centre University of Leicester, Leicester General Hospital Leicester UK

3. NIHR Collaboration for Leadership in Applied Health Research and Care‐East Midlands University of Leicester Leicester UK

4. NIHR Leicester Biomedical Research Centre University Hospitals of Leicester NHS Trust and University of Leicester Leicester UK

Funder

NIHR Leicester Biomedical Research Centre

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14735

Reference31 articles.

1. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

2. Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry: diabetes mellitus ‐ Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.https://www.fda.gov/media/71297/download. Accessed on 11 Jan 2022.

3. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

4. Non-inferiority versus superiority drug claims: the (not so) subtle distinction

5. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management;Diabetologia;2024-08-19

2. Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2024-02

3. Translating trial results into interpretable risk estimates: systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors;Nutrition, Metabolism and Cardiovascular Diseases;2023-12